Mafraq Hospital Becomes First in United Arab Emirates to Deploy Masimo rainbow SET Pulse CO-Oximetry for State-of-the-Art Noninvasive Patient Monitoring

Largest Hospital in the UAE Converts to Pulse CO-Oximetry Technology-Offering Advanced Monitoring of Blood Constituents and Multiple Physiological Parameters Without Invasive Procedures

IRVINE, California and DUBAI, United Arab Emirates, February 10, 2011 - Mafraq Hospital (www.mafraqhospital.ae) and Masimo
(www.masimo.com) (Nasdaq: MASI) jointly announced the hospital-wide
conversion of Mafraq Hospital to Masimo rainbow(R) SET Pulse CO-Oximetry(TM)
technology for advanced noninvasive patient monitoring capabilities. The
conversion makes Mafraq Hospital the first hospital in the UAE to feature
Masimo's technologically and clinically-advanced oximetry and noninvasive
patient monitoring solutions.

The Masimo rainbow SET Pulse CO-Oximetry technology platform allows
hospitals to noninvasively measure and continuously monitor multiple blood
constituents and physiological parameters that previously required invasive
procedures-including: total hemoglobin (SpHb(R))
(www.masimo.com/hemoglobin), oxygen content (SpOC(TM)),
carboxyhemoglobin (SpCO(R)) (www.masimo.com/spco), methemoglobin
(SpMet(R)) (www.masimo.com/spmet), Pleth Variability Index (PVI(R))
(www.masimo.com/pvi ), and acoustic respiration rate (RRa(TM))
(www.masimo.com/rra/index.htm), in addition to the 'gold-standard'
Measure-Through Motion and Low Perfusion performance of Masimo SET(R)
(www.masimo.com/whymasimo/difference.htm) oxyhemoglobin (SpO2),
perfusion index (PI), and pulse rate (PR). The oximetry standard-of-care at
leading hospitals worldwide, Masimo rainbow SET provides immediate real-time
results that enable clinicians to more rapidly assess patients and detect and
treat adverse, potentially life-threatening conditions earlier.

"Mafraq Hospital takes great pride in the skills and experience of its
physicians and the fact that we have some of the world's most advanced
equipment available, so that we can provide the best medical care and
treatment services in one of the fastest growing areas in the Emirate of Abu
Dhabi," stated John Nickens, CEO at Mafraq Hospital. "We saw tremendous value
in the superior performance and futuristic noninvasive capabilities of Masimo
rainbow SET Pulse CO-Oximetry and wanted to extend its positive clinical
impact and patient care benefits to all of our patients throughout the
hospital."

Mafraq Hospital, managed by Bumrungrad International and owned and
operated by the Abu Dhabi Health Services Company PJSC (SEHA), which is
responsible for all the curative activities of public hospitals and clinics
in Abu Dhabi, is a major referral hospital and comprehensive tertiary
healthcare provider in the UAE for 510,000 patients each year. The conversion
ensures that all multiparameter patient monitors, stand-alone oximeters, and
sensors throughout the hospital will feature the advanced noninvasive patient
monitoring capabilities of Masimo rainbow SET-allowing Mafraq Hospital
clinicians to easily and painlessly obtain and continuously track vital blood
and physiological data for patients in real-time. Mafraq Hospital initially
launched the new technology platform hospital-wide with Masimo SET pulse
oximetry measurements (SpO2, PI, and PR), enabling the hospital to quickly
and easily upgrade to Masimo rainbow Pulse CO-Oximetry measurements (SpHb,
SpOC, PVI, SpCO, SpMet) as needed.

According to Mafraq Hospital Chief Nursing Officer, Gail Smith, "This
conversion provides an exciting new medical first-noninvasive and continuous
hemoglobin (SpHb), which allows our clinicians to perform trauma-free
hemoglobin blood tests and get immediate results. And, as the only hospital
in the UAE equipped with SpHb, we not only have the ability to quickly
measure hemoglobin levels without removing a drop of blood from the patient,
but we can now continuously track hemoglobin levels in real-time without
having to perform repeated, painful blood draws and time-consuming lab
analyses."

Masimo Founder and CEO, Joe Kiani, stated, "We are happy to be partnering
with Mafraq Hospital as they lead the UAE in advancing the care and safety of
patients. Mafraq Hospital's adoption of Masimo rainbow SET now makes it
possible for hospital clinicians to noninvasively monitor and continuously
track key indicators of a patient's relative physiological status-including
hemoglobin and other blood constituents as well as fluid volume and
respiration rate-to immediately and painlessly identify abnormalities and
detect potentially life-threatening conditions much earlier."

The CEO of Emitac Healthcare Solutions (EHS), Masimo's distributor in the
UAE, Mr. Raghavan Srinivasan considers it a matter of pride to partner with
Masimo in deploying this solution to Mafraq Hospital, stating that: "This is
a progressive step by the hospital to adopt innovative means to providing
quality healthcare in the country."

About Mafraq Hospital

Mafraq Hospital was established in 1983 and is one of the largest
tertiary referral treatment hospitals in the United Arab Emirates, with 451
licensed beds. Its specialist services include medicine, obstetrics,
pediatrics, as well as surgical and critical care services. Mafraq Hospital
operates the largest burn unit in the country and is a Center of Excellence
for ENT and Thoracic surgery. The hospital also operates two primary
healthcare clinics at Bani Yas and Al Nahda. Mafraq Hospital is part of the
SEHA Health System and is owned and operated by Abu Dhabi Health Services
Company PJSC (SEHA) which is responsible for the curative activities of the
public hospitals and clinics of the Emirate of Abu Dhabi. It is managed by
Bumrungrad International (BIL), one of the most noted hospital management
companies in Asia. Mafraq Hospital physicians are amongst the best in their
specialist fields with international qualifications and world class
expertise. The medical staff is supported by a capable and professional
nursing and paramedical staff who are well trained and motivated to provide
quality healthcare services. Emiratization is extremely important to Mafraq
Hospital and many of the hospital's highly skilled physicians are UAE
Nationals. The hospital also believes in customer service excellence and in
providing quality healthcare with integrity and service excellence in a
caring environment.

About the SEHA Health System and the Abu Dhabi Health Services Company
PJSC (SEHA)

SEHA is health in Arabic. The Abu Dhabi Health Services Company PJSC -
whose marketing identity is SEHA - is an independent, public joint stock
company created to develop the curative activities of the public healthcare
system in Abu Dhabi. The company owns and operates all the public hospitals
and clinics of the Emirate of Abu Dhabi which together make up the SEHA
Health System. SEHA is committed to providing high quality, cost effective
healthcare in a socially responsible way on par with international standards
measured through accessibility, affordability, choice and satisfaction. SEHA
has partnered with internationally recognized hospital managers to achieve
these goals. These include Johns Hopkins Medicine International, Cleveland
Clinic Foundation, VAMED, Vienna Medical University and Bumrungrad
International. SEHA owns and operates 12 hospitals with 2,644 beds, 62
ambulatory care, family care and urgent care centers and 2 blood banks. SEHA
is one of the largest integrated healthcare providers in the Middle East with
16,500 doctors, nurses, ancillary care and administrative personnel in its
employ. For more information, visit www.seha.ae.

About Masimo

Masimo (NASDAQ: MASI) develops innovative monitoring technologies that
significantly improve patient care-helping solve "unsolvable" problems. In
1995, the company debuted Measure-Through Motion and Low Perfusion pulse
oximetry, known as Masimo SET(R), which virtually eliminated false alarms and
increased pulse oximetry's ability to detect life-threatening events. More
than 100 independent and objective studies demonstrate Masimo SET provides
the most reliable SpO2 and pulse rate measurements even under the most
challenging clinical conditions, including patient motion and low peripheral
perfusion. In 2005, Masimo introduced rainbow(R) Pulse CO-Oximetry(TM),
allowing noninvasive and continuous monitoring of blood constituents that
previously required invasive procedures, including total hemoglobin
(SpHb(R)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)),
methemoglobin (SpMet(R)), and Pleth Variability Index (PVI(R)), in addition
to SpO2, pulse rate, and perfusion index (PI). In 2009, Masimo introduced
rainbow Acoustic Monitoring(TM), the first-ever noninvasive and continuous
monitoring of acoustic respiration rate (RRa(TM)). Masimo's rainbow SET
platform offers a breakthrough in patient safety by helping clinicians detect
life-threatening conditions and helping guide treatment options. Founded in
1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost
of Care … by Taking Noninvasive Monitoring to New Sites and
Applications(R)." Additional information about Masimo and its products may be
found at www.masimo.com.

Forward Looking Statements

This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, in connection with the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are based on current
expectations about future events affecting us and are subject to risks and
uncertainties, all of which are difficult to predict and many of which are
beyond our control and could cause our actual results to differ materially
and adversely from those expressed in our forward-looking statements as a
result of various risk factors, including, but not limited to: risks related
to our assumptions that the hospital-wide conversion ensures that all Mafraq
patients will be cared for using the most technologically and
clinically-advanced noninvasive patient monitoring solutions available; risks
related to our belief that Masimo rainbow SET provides real-time results for
all patients to help clinicians to more rapidly assess, diagnose, and treat
every patient; risks related to our belief that SpHb detects low or falling
hemoglobin levels that could be the result of internal bleeding; as well as
other factors discussed in the "Risk Factors" section of our most recent
reports filed with the Securities and Exchange Commission ("SEC"), which may
be obtained for free at the SEC's website at www.sec.gov. Although we believe
that the expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove correct. All
forward-looking statements included in this press release are expressly
qualified in their entirety by the foregoing cautionary statements. You are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of today's date. We do not undertake any obligation to
update, amend or clarify these forward-looking statements or the "Risk
Factors" contained in our most recent reports filed with the SEC, whether as
a result of new information, future events or otherwise, except as may be
required under the applicable securities laws.

    Media Contacts:
    Amanda Banham                      Dana Banks
    Mafraq Hospital                    Masimo Corporation
    +971-2-5012443                     +1-949-297-7348
    abanham@mafraqhospital.ae          dbanks@masimo.com

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and
Reducing Cost of Care by… Taking Noninvasive Monitoring to New Sites and
Applications, rainbow, Pulse CO-Oximetry, Pulse CO-Oximeter, SpHb, SpOC,
SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87,
Rad-57, Rad-8, Rad-5, Pronto-7, Pronto, Patient SafetyNet, and SEDLine are
trademarks or registered trademarks of Masimo Corporation.

Amanda Banham of Mafraq Hospital, +971-2-5012443, abanham at mafraqhospital.ae; or Dana Banks of Masimo Corporation, +1-949-297-7348, dbanks at masimo.com